Advancing global programmatic management of latent tuberculosis infection for at risk populations

Eur Respir J. 2016 May;47(5):1327-30. doi: 10.1183/13993003.00449-2016.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antitubercular Agents*
  • Humans
  • Latent Tuberculosis*
  • Risk Factors
  • Tuberculosis

Substances

  • Antitubercular Agents